Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.
Wensheng JiangHuanqing ChengLili YuJie ZhangYihui WangYun LiangFeng LouHuina WangShanbo CaoPublished in: Cancer medicine (2022)
This study provided important insights into the molecular-clinical profile of TP53-mutated NSCLC patients. Moreover, the data revealed that EAp53 high-risk mutations were an independent prognostic factor for worse OS in advanced NSCLC.
Keyphrases
- advanced non small cell lung cancer
- prognostic factors
- poor prognosis
- epidermal growth factor receptor
- small cell lung cancer
- long non coding rna
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- case report
- single cell
- big data
- machine learning
- tyrosine kinase
- genome wide
- single molecule